Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

@article{Schouten2010SubstitutionON,
  title={Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.},
  author={Jeffrey Thomas Schouten and Amy Krambrink and Heather Ribaudo and Anne Kmack and Nancy Webb and Cecilia Shikuma and Daniel R. Kuritzkes and Roy M. Gulick},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2010},
  volume={50 5},
  pages={787-91}
}
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 . 

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-8 of 8 references

Similar Papers

Loading similar papers…